Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
In a release, Amarin said the committee would likely target the results of Vascepa’s Reduce-It outcomes trial, which showed a 26% risk reduction for cardiovascular events over placebo. Those trial resuls, unveiled in October, were touted as a “landmark” achievement for Vascepa and a potential sign of a blockbuster drug in the making.
